Edition:
India

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

2.50USD
23 Aug 2019
Change (% chg)

$-0.07 (-2.72%)
Prev Close
$2.57
Open
$2.56
Day's High
$2.68
Day's Low
$2.49
Volume
421,760
Avg. Vol
551,667
52-wk High
$9.94
52-wk Low
$2.49

Latest Key Developments (Source: Significant Developments)

BioCryst Reports Second Quarter 2019 Financial Results
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.34.Q2 REVENUE $1.4 MILLION VERSUS $12.5 MILLION.Q2 REVENUE ESTIMATE $2 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.DATA FROM ONGOING PHASE 1 TRIAL OF ORAL FACTOR D INHIBITOR, BCX9930, EXPECTED IN Q4 2019.BIOCRYST PHARMACEUTICALS - NEW DRUG APPLICATION FOR ONCE-DAILY ORAL BCX7353 FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS ON-TRACK FOR SUBMISSION.PLANS TO BEGIN ZENITH-2, A PHASE 3 CLINICAL TRIAL OF ORAL BCX7353 (750 MG) FOR ACUTE TREATMENT OF HAE IN 2020.PREPARING FOR COMMERCIAL LAUNCH OF BCX7353 IN U.S. LATER IN 2020.QTRLY TOTAL REVENUES WERE $1.4 MILLION, COMPARED TO $12.5 MILLION IN Q2 OF 2018.NET LOSS FOR Q2 OF 2019 WAS $37.6 MILLION, OR $0.34 PER SHARE.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $97.5 MILLION AT JUNE 30, 2019.  Full Article

BioCryst Reports Third Quarter 2018 Financial Results
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.28.Q3 REVENUE $1.5 MILLION VERSUS $8.8 MILLION.Q3 REVENUE VIEW $3.8 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.25 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $151.0 MILLION AT SEPTEMBER 30, 2018.  Full Article

Biocryst Reports Agreement With PMDA On Phase 3 Clinical Trial of BCX7353 In Japan
Monday, 25 Jun 2018 

June 25 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS AGREEMENT WITH PMDA ON PHASE 3 CLINICAL TRIAL AND REGULATORY REQUIREMENTS FOR MARKETING AUTHORIZATION OF BCX7353 IN JAPAN.BIOCRYST REPORTS AGREEMENT WITH PMDA ON PHASE 3 CLINICAL TRIAL AND REGULATORY REQUIREMENTS FOR MARKETING AUTHORIZATION OF BCX7353 IN JAPAN.BIOCRYST PHARMACEUTICALS-AGREEMENT ON DESIGN OF PHASE 3 TRIAL & REGULATORY REQUIREMENTS FOR MARKETING AUTHORIZATION OF BCX7353 FOR HAE WITH PMDA IN JAPAN.  Full Article

Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger
Tuesday, 10 Apr 2018 

April 10 (Reuters) - Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo ::BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS RESCHEDULE MEETINGS TO VOTE ON PROPOSED MERGER.BIOCRYST AND IDERA SPECIAL MEETINGS TO BE HELD ON JULY 10, 2018.NEW CLINICAL DATA ON IDERA'S IMO-2125 PROGRAM WILL BE AVAILABLE PRIOR TO VOTE.IDERA BOARD UNANIMOUSLY RECOMMENDS THAT IDERA STOCKHOLDERS VOTE "FOR" PROPOSED MERGER AT IDERA SPECIAL MEETING.  Full Article

RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals
Monday, 2 Apr 2018 

April 2 (Reuters) - Idera Pharmaceuticals Inc ::RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS.‍RA CAPITAL MANAGEMENT SAYS HAS BENEFICIAL OWNERSHIP OF ABOUT 7.1 PERCENT OF BIOCRYST PHARMACEUTICALS' COMMON STOCK​.RA CAPITAL SAYS HAS "SERIOUS CONCERNS" ABOUT BIOCRYST PHARMACEUTICALS' PROPOSED DEAL WITH IDERA AND ITS "DILUTIVE IMPACT" ON BIOCRYST SHAREHOLDERS ‍​.  Full Article

Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals
Monday, 2 Apr 2018 

April 2 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS.‍BIOCRYST SPECIAL MEETING OF STOCKHOLDERS SCHEDULED FOR MAY 9, 2018​.‍RECOMMEND THAT ALL CO'S STOCKHOLDERS VOTE "FOR" MERGER PROPOSAL WITH IDERA PHARMA​.‍RECOMMEND STOCKHOLDERS VOTE "FOR" BIOCRYST PROPOSALS SET FORTH IN PROXY STATEMENT, INCLUDING "FOR" MERGER PROPOSAL​.  Full Article

Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema
Thursday, 15 Mar 2018 

March 15 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA.BIOCRYST PHARMACEUTICALS INC SEES REPORTING TOP-LINE RESULTS FROM APEX-2 PHASE 3 TRIAL IN FIRST HALF OF 2019.  Full Article

Biocryst Reports Q4 Loss Per Share of $0.20
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.20.Q4 REVENUE $3.9 MILLION VERSUS $9.0 MILLION.CASH, CASH EQUIVALENTS & INVESTMENTS TOTALED $159.0 MILLION AT DEC 31, 2017, REFLECTS INCREASE FROM $65.1 MILLION AT DEC 31, 2016.EXPECTS ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $67 TO $90 MILLION.SEES 2018 OPERATING EXPENSES TO BE IN RANGE OF $85 TO $110 MILLION.  Full Article

Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma
Friday, 16 Feb 2018 

Feb 16 (Reuters) - Great Point Partners LLC::GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC..‍GREAT POINT PARTNERS, LLC SAYS BENEFICIALLY OWNING ABOUT 7.5 MILLION SHARES OF COMMON STOCK OF BIOCRYST PHARMACEUTICALS​.GREAT POINT PARTNERS SAYS BELIEVE BIOCRYST PHARMA'S SHARES ARE "UNDERVALUED".GREAT POINT PARTNERS SAYS BELIEVE IT IS "INCUMBENT" UPON BIOCRYST PHARMACEUTICAL BOARD TO EXPLORE ALTERNATIVE STRATEGIES.  Full Article

BioCryst Pharma files for mixed shelf of up to $200 million‍​
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - BioCryst Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing‍​.  Full Article